Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases.
$10.29+16.01%
报价 2026-11-06
市值
$591M
EV
$552.4M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -42.3%
$1.64$17.84
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CLYMClimb Bio, Inc. | $591M | +16.0% | – | 0% | – | – | – | |
| ENTXEntera Bio Ltd. | $546.1M | +5.0% | – | 0% | – | – | – | |
| AGENAgenus Inc. | $322.9M | +11.0% | +26.2% | 76.5% | 9.7x | 3.4x | – | |
| TTRXTurn Therapeutics Inc. | $287.9M | +6.0% | – | 0% | – | – | – | |
| ANIXAnixa Biosciences, Inc. | $110.4M | +4.8% | -71.7% | 0% | – | – | – | |
| INOInovio Pharmaceuticals, Inc. | $83.9M | -16.2% | +10800.0% | 0% | – | – | – | |
| SPROSpero Therapeutics, Inc. | $60M | +1.0% | -96.9% | 100% | 9.7x | 3.9x | 4.0x | |
| MCRBSeres Therapeutics, Inc. | $19.7M | -5.3% | +133.3% | -20.9% | – | – | – | |
| ABOSAcumen Pharmaceuticals, Inc. | $16.2M | +4.5% | -100.0% | 0% | – | – | – | |
| 同行中位数 | – | – | -22.7% | 0% | 9.7x | 3.6x | 4.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。